Veeda Lifesciences | Unlisted Share Research Report
Sector: Contract Research Organisation (CRO) / Life Sciences
Company: Veeda Clinical Research Limited
Brand: Veeda Lifesciences
CIN: U73100GJ2004PLC044023
ISIN: INE01HQ01026
Face Value: ₹2 per share
Registered Office: Ahmedabad, Gujarat
Status: Unlisted Public Company / IPO Candidate
1. Company Overview
Veeda Clinical Research Limited, now operating under the Veeda Lifesciences brand, is an Indian contract research organisation providing research and development services to pharmaceutical, biotechnology and life-sciences companies.
The company was established in 2004 and has evolved from a primarily India-focused clinical research company into a broader integrated drug-development platform with operations extending into preclinical research and international clinical trials.
Its registered office is in Ahmedabad, Gujarat.
Veeda Lifesciences – Official Website
Veeda – Financial Reports & Disclosures
2. What Does Veeda Actually Do?
Veeda operates in the CRO — Contract Research Organisation industry.
Instead of pharmaceutical companies carrying out every stage of drug research internally, they outsource portions of research, testing and clinical development to specialised CROs such as Veeda.
The group’s capabilities span areas including:
Preclinical research → Bioavailability/Bioequivalence → Early-phase clinical research → Clinical trials → Data management → Biostatistics → Regulatory support → Late-phase and specialty clinical research.
This gives Veeda exposure to the broader pharmaceutical R&D outsourcing opportunity rather than depending on the commercial success of a single drug.
3. Integrated CRO Platform
Veeda has built its platform around three important businesses.
Veeda Clinical Research
The original clinical-research business provides human clinical research, bioavailability and bioequivalence studies and related drug-development services.
Bioneeds India
Bioneeds expanded the group into preclinical and laboratory research, allowing Veeda to participate earlier in the drug-development cycle.
Third-party shareholding data indicates Veeda owns approximately 87% of Bioneeds India.
Heads / Health Data Specialists
Veeda expanded internationally through Health Data Specialists (Heads), adding capabilities particularly in international and late-phase clinical research. The FY25 consolidated accounts include Health Data Specialists operations across Ireland, the Netherlands, Germany, Italy, Switzerland, the US and Australia, among other jurisdictions.
The strategic direction is therefore:
Preclinical → Clinical → Global Clinical Trials
rather than remaining only a traditional bioequivalence CRO.
4. Why This Business Model Is Interesting
Drug development is expensive, specialised and highly regulated.
Pharma and biotech companies can outsource parts of development to CROs instead of building every research capability internally.
For Veeda, this creates multiple revenue opportunities across the life cycle of a pharmaceutical molecule.
A successful integrated CRO can potentially increase revenue per customer by providing several services rather than performing only one clinical study.
5. FY2025 Financial Performance
Veeda’s FY25 annual report shows a major increase in consolidated revenue.
| Particulars | FY24 | FY25 | Change |
|---|---|---|---|
| Revenue from Operations | ₹388.78 Cr | ₹609.73 Cr | +56.8% |
| Other Income | ₹19.21 Cr | ₹11.41 Cr | — |
| Consolidated PAT/(Loss) | ~₹(0.36) Cr | ₹(66.81) Cr | Loss widened |
| EPS | ₹(0.04) | ₹(10.57) | — |
The official annual report reports consolidated revenue from operations of ₹6,097.26 million in FY25 versus ₹3,887.77 million in FY24, representing very strong top-line expansion.
However, consolidated loss for FY25 was approximately ₹668.11 million (₹66.81 crore) versus a small loss of ₹3.58 million in FY24. Loss attributable to equity shareholders of the parent was approximately ₹67.84 crore.
The key point
Revenue grew nearly 57%, but profitability deteriorated sharply.
Therefore, the central investment question around Veeda is currently not revenue growth alone—it is whether the expanded international CRO platform can convert this growth into sustainable EBITDA and PAT.
6. Why Did Profitability Weaken?
FY25 was an expansion and integration-heavy year.
One notable expense in the accounts was approximately ₹14.56 crore of share-based payment expense, compared with effectively nil in FY24.
The company has also been integrating acquired businesses and building a much larger international research platform.
This means investors should distinguish between:
Structural operating profitability
and
acquisition/integration, ESOP and expansion-related costs.
The next few reporting periods are therefore important for determining whether operating leverage emerges from the larger revenue base.
7. Revenue Scale Has Changed Significantly
Veeda is no longer a small ₹200–300 crore clinical-research business.
Consolidated revenue reached approximately:
₹610 crore in FY25
from approximately:
₹389 crore in FY24
That scale-up is strategically important because CRO economics can improve materially if utilisation, customer mix and project execution improve as the platform grows.
8. Global Expansion
Veeda’s acquisition strategy has materially expanded its international footprint.
The FY25 consolidated financial statements show subsidiaries and operations linked to markets including:
- India
- Ireland
- Netherlands
- Germany
- Italy
- Switzerland
- United States
- Australia
- Greece
among other international markets.
This reduces Veeda’s dependence on only the Indian pharmaceutical research market and provides access to global biotech and pharmaceutical clients.
However, international expansion also brings higher employee costs, integration complexity, currency exposure and execution risk.
9. Subsidiary Structure
Important businesses within the Veeda ecosystem include:
| Business | Role |
|---|---|
| Veeda Clinical Research | Clinical CRO |
| Bioneeds India | Preclinical CRO |
| Amthera Life Sciences | Step-down subsidiary |
| Veeda Clinical Research Ireland | International operations |
| Health Data Specialists / Heads | Global clinical research platform |
Third-party shareholding information reports Veeda’s stake in Bioneeds at approximately 87%, with Amthera being a step-down subsidiary through Bioneeds.
10. IPO Plans
This is one of the most important developments for unlisted investors.
Veeda Clinical Research filed its Draft Red Herring Prospectus with SEBI in early 2025. SEBI’s official public-issue database records the draft offer filing on 5 February 2025.
SEBI – Veeda Clinical Research IPO Filing
The proposed IPO structure in the draft documents consisted of:
Fresh Issue: up to ₹185 crore
plus
Offer for Sale: up to approximately 1.30 crore equity shares.
The IPO is proposed for listing on NSE and BSE.
SEBI subsequently cleared Veeda’s IPO proposal in July 2025. Reuters also reported in July 2025 that Veeda was among the companies whose IPOs had received regulatory approval.
Current position – September 2026
Despite regulatory approval, a final IPO price band, opening date and listing date have not been announced in the sources reviewed.
Therefore, the IPO should be considered approved/proposed but not yet launched, rather than a confirmed near-term listing.
11. Shareholding
Third-party unlisted-market data reports the following broad shareholding pattern as of 31 March 2026:
| Category | Shares | Holding |
|---|---|---|
| Promoters | 2.23 Cr | 31.85% |
| Public / Other Investors | 4.76 Cr | 68.15% |
| Total | 6.99 Cr | 100% |
The relatively large outside-investor ownership reflects the institutional capital Veeda has raised while expanding the business.
12. Unlisted Share Price
Veeda shares currently trade in India’s private/unlisted market.
One current market reference shows:
Indicative Price: ~₹428 per share
with a quoted lot size of 100 shares.
Another unlisted-market platform recently showed a last traded price around ₹445.
Therefore, a reasonable observed OTC reference range is approximately:
₹425–₹450 per share
These are indicative private-market quotes, not NSE/BSE prices. Actual transaction prices can vary based on quantity, seller, buyer, liquidity and settlement terms.
13. Indicative Valuation
Using approximately 6.99 crore shares reported for FY26 and an OTC reference price around ₹428:
Implied Equity Value ≈ ₹2,990 crore
The exact valuation will vary depending on the fully diluted share count, ESOPs and transaction price.
A third-party platform using a lower share-count basis of 6.58 crore currently shows market capitalisation of approximately ₹2,815 crore at ₹428 per share.
This difference is important.
Investors should use the latest fully diluted share count rather than relying only on the headline unlisted share price.
Because FY25 consolidated earnings were negative, conventional trailing P/E is not meaningful.
For Veeda, investors may find metrics such as:
EV/Revenue, EV/EBITDA, future normalised EBITDA margin and valuation versus comparable CRO/CDMO businesses
more useful until consolidated profitability normalises.
14. Growth Drivers
Global pharma R&D outsourcing
Pharmaceutical and biotech companies increasingly use specialist CROs for drug-development activities.
Integrated drug-development platform
Combining Bioneeds, Veeda and Heads potentially allows the group to serve customers from preclinical development through clinical research.
International expansion
The Heads acquisition gives Veeda access to a broader international customer and clinical-trial network.
Cross-selling
A client using preclinical services can potentially be moved into clinical-development services as the molecule advances.
India advantage
India offers a combination of scientific talent, pharmaceutical manufacturing capabilities and comparatively competitive research costs.
IPO possibility
A future NSE/BSE listing could potentially improve liquidity and price discovery for existing shareholders, although the timing remains uncertain.
15. Key Risks
Profitability risk
The biggest near-term issue is clear:
₹610 crore FY25 revenue but approximately ₹67 crore consolidated loss.
Revenue growth needs to translate into sustainable earnings.
Acquisition integration
Veeda has expanded through acquisitions. Integration problems can affect margins and management focus.
International operating costs
Global clinical-research operations can carry materially higher employee and operating costs.
Regulatory risk
Clinical and preclinical research operates under strict domestic and international regulatory standards.
Customer concentration
Large CRO contracts can create dependency on important pharmaceutical and biotech customers.
Clinical-trial risk
Projects can be delayed, cancelled or terminated because of unsuccessful drug development, regulatory issues or customer decisions.
Currency risk
International operations create foreign-exchange exposure.
IPO timing
SEBI approval does not guarantee when the IPO will actually launch.
Unlisted liquidity
Until listing, investors face lower liquidity and potentially significant bid-ask spreads.
Valuation risk
At roughly ₹3,000 crore implied equity value while consolidated earnings remain negative, future profitability improvement is an important assumption behind the valuation.
16. What Investors Should Track
The next financial disclosures are particularly important. Key numbers to watch are consolidated revenue growth, EBITDA margin, PAT, operating cash flow, Heads profitability, Bioneeds growth, international revenue contribution, employee costs, debt, order backlog and any updated IPO filing or launch announcement.
The most important signal would be Veeda demonstrating that its larger ₹600+ crore revenue platform can produce consistent positive EBITDA, cash flow and net profit.
17. UnlistedCart Takeaway
Veeda Clinical Research is evolving from an Indian clinical-research company into a much broader global life-sciences CRO platform.
The strategic story is attractive:
Bioneeds → Preclinical Research
Veeda → Clinical Research
Heads → Global & Late-Phase Clinical Trials
FY25 demonstrated that the strategy is producing strong revenue growth, with consolidated revenue increasing approximately 57% to ₹610 crore.
But the other side of the story is equally important: the company recorded a consolidated loss of approximately ₹66.8 crore, meaning the enlarged platform has not yet demonstrated normalised profitability.
At an indicative unlisted price of roughly ₹425–₹450, Veeda is valued at around ₹3,000 crore, depending on the share-count basis and OTC transaction price.
Therefore, the major variables are:
Can ₹600+ crore revenue move toward ₹800–1,000 crore?
Can the global business achieve healthy EBITDA margins?
Can Veeda return to sustainable consolidated profitability?
And when will the already-approved IPO actually reach the market?
If those pieces come together, the business would look very different from the Veeda of a few years ago. Until then, profitability, valuation and IPO timing remain the key areas to monitor.
Important Links
Veeda Lifesciences – Official Website
Veeda – Financial Reporting & Annual Reports
SEBI – Veeda Clinical Research IPO Filing
Disclaimer: This report is for educational and informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Unlisted shares involve liquidity, valuation, settlement and listing risks. OTC prices are indicative and can vary materially. IPO approval does not guarantee an IPO launch or listing. Investors should independently verify the latest financial statements, capital structure, regulatory filings and transaction terms before investing.
For more such unlisted stocks visit UnlistedCart – Unlisted Shares
